eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

6/2018
vol. 10
 
Share:
Share:
more
 
 
abstract:
Original paper

Outcomes of I-125 brachytherapy for uveal melanomas depending on irradiation dose applied to the tumor apex – a single institution study

Joanna Kowal, Anna Markiewicz, Magdalena Dębicka-Kumela, Anna Bogdali, Bożena Romanowska-Dixon

J Contemp Brachytherapy 2018; 10, 6: 532–541
Online publish date: 2018/11/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose
The aim of the study was an evaluation of I-125 brachytherapy patients with uveal melanoma with special consideration for the relationship of the treatment results and the irradiation dose applied to the tumor apex.

Material and methods
Medical records of 344 adults with uveal melanoma treated with I-125 brachytherapy in the Department of Ophthalmology and Ocular Oncology of the Jagiellonian University, Medical College in Cracow, Poland were retrospectively analyzed. The study was conducted between 2003 and 2012, and the study group was divided into two subgroups depending on the irradiation dose applied to the top of the tumor: 80 Gy to 100 Gy (n = 177) and 100 Gy to 120 Gy (n = 167).

Results
It was found that the height of the tumor and the largest diameter of the tumor base decreased with every consecutive follow-up measurement and differed significantly in all comparisons (p < 0.0001). No significant correlation between frequency of complications was found between both study groups (χ2 = 0.27; p = 0.6067). The correlation between survival and the irradiation dose as applied to the tumor top was statistically irrelevant (χ2 = 0.44; p = 0.5084). A logistic regression model showed that patient survival depended on the largest diameter of the base and the height of tumor (p = 0.0216), and the risk of death was larger as these dimensions increased (IR, 1.17). An increase of the largest diameter of the base by 1 mm meant a 17% increase in chances of death. In 13.4% of cases, an enucleation was necessary.

Conclusions
The treatment of choroidal melanomas with I-125 iodine isotope brachytherapy is an efficient and recommended method of treatment and in many cases, an alternative to the enucleation of an eyeball.

keywords:

I-125 brachytherapy, irradiation dose, ocular melanoma, uveal melanoma

references:
Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye 2017; 31: 241-257.
Shields JA, Shields CL. Intraocular Tumors. WB Saunders Co, Philadelphia 1992; 25-43, 51-59, 66-77, 118-136, 156-169, 171-205.
Proniewska-Skrętek E, Wojnar M, Mariak Z, Zalewska R. Genetic abnormalities underlying formation of choroidal melanoma. Klin Oczna 2005; 107: 140-142.
Isager P, Ehlers N, Overgaard J. Have choroidal and ciliary body melanomas changed during the period 1955-2000? Acta Ophtalmol Scand 2004; 82: 509-516.
Romanowska-Dixon B, Pogrzebielski A, Bogdali A et al. Proton beam radiotherapy of uveal melanoma – preliminary results. Klin Oczna 2012; 114: 173-179.
Żygulska-Mach H. Epidemiologia czerniaka oka. Współcz Onkol 1998; 2: 226-227 [in Polish].
Shields CL, Furuta M, Thangappan A et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 2009; 127: 989-998.
Diener-West M, Hawkins BS, Markowitz JM, Schachat AP. A review of mortality from choriodal melanoma, II: meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophtalmol 1992; 110: 245-250.
Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 11: 4651-4659.
Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res 2011; 30: 285-295.
Gill HS, Char DH. Uveal melanoma prognostication: from lesion size and cell type to molecular class. Can J Ophthalmol 2012; 47: 246-253.
Damato B, Coupland SE. Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol 2009; 127: 423-429.
Triozzi PL, Singh AD. Adjuvant therapy of uveal melanoma: current status. Ocul Oncol Pathol 2014; 1: 54-62.
Weis E, Salopek TG, McKinnon JG et al. Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol 2016; 23: e57-e64.
Mariani P, Piperno-Neumann S, Servois V et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol 2009; 35: 1192-1197.
Gonsalves CF, Eschelman DJ, Thornburg B et al. Uveal melanoma metastatic to the liver: Chemoembolization with 1,3-bis-(2-chloroethyl)-1-nitrosourea. AJR Am J Roentgenol 2015; 205: 429-433.
Carling U, Dorenberg EJ, Haugvik SP et al. Transarterial chemoembolization of liver metastases from uveal melanoma using irinotecan-loaded beads: treatment response and complications. Cardiovasc Intervent Radiol 2015; 38: 1532-1541.
Valsecchi ME, Terai M, Eschelman DJ et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol 2015; 26: 523-532.e2.
Oliva M, Rullan AJ, Piulats JM. Uveal melanoma as a target for immune-therapy. Ann Transl Med 2016; 4: 172.
Rao HJ, Sein J, Badiyan S et al. Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis. J Contemp Brachytherapy 2017; 9: 453-465.
Diener-West M, Earle JD, Fine SL et al.; Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119: 969-982.
Leonard KL, Gagne NL, Mignano JE et al. A 17-year retrospective study of institutional results for eye plaque brachytherapy of uveal melanoma using (125) I, (103) Pd, and (131) Cs and historical perspective. Brachytherapy 2011; 10: 331-339.
The American Brachytherapy Society – Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13: 1-14.
Collaborative Ocular Melanoma Study Group. The COMS randomize trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124: 1684-1693.
Miguel D, de Frutos-Baraja JM, Lopez-Lara F et al. Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses. J Contemp Brachytherapy 2018; 10: 123-131.
Wagner A, Chen A, Cook T et al. Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience. ISRN Ophthalmol 2014; 2014: 950975.
Echegaray JJ, Bechrakis NE, Singh N et al. Iodine-125 brachytherapy for uveal melanoma: a systematic review of radiation dose. Ocul Oncol Pathol 2017; 3: 193-198.
Demirci H, Saponara F, Khan A et al. Regression rate of posterior uveal melanomas following Iodine-125 plaque radiotherapy. Afr J Ophthalmol 2015; 22: 103-107.
Garcia-Álvarez C, Saornil MA, López-Lara F et al. Episcleral brachytherapy for uveal melanoma: analysis of 136 cases. Clin Transl Oncol 2012; 14: 350-355.
Rashid M, Heikkonen J, Kivelä T. Tumor regression after brachytherapy for choroidal melanoma: reduction of thickness and cross sectional area by shape and regression pattern. Invest Ophthalmol Vis Sci 2015; 56: 2612-2623.
Jampol LM, Moy CS, Murray TG et al. For the COMS Follow-up of Plaque Eyes Working Group: The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma IV. Local Treatment Failure and Enucleation in the First 5 Years after Brachytherapy, COMS Report No. 19. Ophthalmology 2002; 109: 2197-2206.
Szuścik I, Romanowska-Dixon B, Markiewicz A et al. Neuropatia popromienna po brachyterapii czerniaka naczyniówki. (Radiation optic neuropathy after brachytherapy of uveal melanoma). Klin Oczna 2006; 108: 278-280.
Shields CL, Naseripour M, Cater J et al. Plaque radiotherapy for large posterior uveal melanomas (> or = 8-mm thick) in 354 consecutive patients. Ophthalmology 2002; 109: 1838-1849.
Gagne NL, Cutright DR, Rivard MJ. Keeping an eye on the ring: COMS plaque loading optimization for improved dose conformity and homogeneity. J Contemp Brachytherapy 2012; 4: 165-175.
Wen JC, Oliver SC, McCannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye 2009; 23: 1254-1268.
Chang MY, Kamrava M, Demanes DJ et al. Intraoperative ultrasonography-guided positioning of Iodine 125 plaque brachytherapy in the treatment of choroidal melanoma. Ophthalmology 2012; 119: 1073-1077.
Chang MY, McCannel TA. Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmol 2013; 97: 804-811.
Caminal Mitjana JM, Quintana Casany M, Pera Fábregas J et al. Results of Iodine-125 radiotherapy in the treatment of uveal melanoma. Arch Soc Esp Oftalmol 2002; 77: 29-38.
Shields CL, Bianciotto C, Rudich D et al. Regression of uveal melanoma after plaque radiotherapy and thermotherapy based on chromosome 3 status. Retina 2008; 28: 1289-1295.
Marathe OS, Wu J, Lee SP et al. Ocular response of choroidal melanoma with monosomy 3 versus disomy 3 after Iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 2011; 81: 1046-1048.
Respond-Kubiak I, Wróblewska-Zierhoffer M, TwardoszPawlik H et al. Ruthenium brachytherapy for uveal melanoma – single institution experience. J Contemp Brachytherapy 2017; 9: 548-552.
Damato B, Patel I, Campbell IR et al. Local tumor control after 106 Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol 2005; 63: 385-391.
Rouberol F, Roy P, Kodjikian L et al. Survival, anatomy, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays). Ophthalmology 2004; 137: 893-900.
Ophthalmic Oncology Task Force. Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology 2016; 123: 86-91.
Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye 2012; 26: 1157-1172.
 
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe